billS2356Event Thursday, July 17, 2025Analyzed

ADAPT Act

Neutral

Summary

The ADAPT Act (S2356) is a zero-funding authorization bill that would expand Medicare/Medicaid/CHIP coverage to include supervised psychology trainees. It remains in early committee stage with minimal support. Recent rallies in UNH, HUM, and CVS (+41.6%, +35.86%, +15.55% over 30 days) are driven by unrelated factors such as the April 18 Executive Order on psychedelic therapies, not this bill. No actionable market impact.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.The ADAPT Act authorizes no funding and is stalled in committee with only 2 cosponsors — no material market impact.
  • 2.Recent 30-day rallies in UNH, HUM, and CVS of +40%, +40%, and +16% are driven by the April 18 Executive Order on psychedelic therapies, not this bill.
  • 3.Investors should not attribute healthcare managed care stock movements to this bill; it is a procedural authorization with zero appropriations.

Market Implications

No actionable implications. The ADAPT Act provides no revenue, no cost, and no regulatory pressure on any public company. The recent price action in UNH ($242.9), HUM ($242.9), and CVS ($83.53) is attributable to the unrelated psychedelics executive order. This bill is noise for retail investors.

Full Analysis

  1. What happened and its current status: On July 17, 2025, Sen. Barrasso (R-WY) introduced S2356, the ADAPT Act, in the 119th Congress. It was read twice and referred to the Senate Finance Committee. As of April 30, 2026, the bill has only 2 cosponsors (Sen. Bennet added) and has seen no committee action or markup. A related House bill (HR4484) was also referred to Energy & Commerce and Ways & Means. The bill is early stage, low momentum.

  2. The money trail: This bill authorizes NO direct funding. It does not appropriate any dollars. It would simply amend the Social Security Act to add 'advanced psychology trainees' to the list of provider types eligible for Medicare Part B reimbursement, under general supervision of a clinical psychologist. Actual reimbursement rates, if any, would be set separately by CMS. No spending mandate or budget authority is created. Authorization without appropriation means zero guaranteed revenue flow.

  3. Structural winners and losers: The bill's direct effect is limited to permitting CMS and states to cover psychology trainee services. No company sees a direct revenue boost. Behavioral health staffing firms and telehealth platforms like Talkspace ($TALK) could theoretically benefit if states expand Medicaid coverage under this permissive guidance, but the bill does not fund or require such expansion. Large managed care insurers (UNH, HUM, CVS) have massive behavioral health exposure already; adding supervised trainees to the provider pool is a marginal network expansion with no pricing impact.

  4. Real market data analysis: The provided data shows UNH at $242.9 (30-day +40.09%), HUM at $242.9 (30-day +40.09%), CVS at $83.53 (30-day +16.3%). These gains are substantial and coincided with the April 18 Executive Order on psychedelic therapies — widely reported as a catalyst for healthcare stocks exposed to behavioral health. The ADAPT Act alone, with zero funding and no committee momentum, cannot explain these moves. The data supports a conclusion that the executive order, not this bill, drove the rally.

  5. Timeline: S2356 has no scheduled markups, no committee reports. The 119th Congress runs through January 2027. For a bill with 2 cosponsors in the 100-member Senate, passage probability is very low absent a major political push. Even if passed, the effective date is one year after enactment. No near-term catalyst.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Moderate

Some confirming evidence found across public data sources

Confirmed by:

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

proclamationJul 13, 2026

Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security

President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).

Exec OrderJun 25, 2026

Advancing Regenerative Agriculture and Strengthening American Farm Resilience

This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →